Briacell Therapeutics (BCT) Trading Up 13.6%
Briacell Therapeutics Corp (CVE:BCT)’s share price was up 13.6% during trading on Wednesday . The company traded as high as C$0.13 and last traded at C$0.13. Approximately 682,200 shares traded hands during mid-day trading, an increase of 125% from the average daily volume of 303,817 shares. The stock had previously closed at C$0.11.
The company has a quick ratio of 0.85, a current ratio of 0.96 and a debt-to-equity ratio of 228.18. The company has a market capitalization of $17.75 million and a P/E ratio of -2.93.
Briacell Therapeutics (CVE:BCT) last posted its quarterly earnings data on Friday, December 28th. The company reported C($0.01) EPS for the quarter.
ILLEGAL ACTIVITY NOTICE: “Briacell Therapeutics (BCT) Trading Up 13.6%” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://theolympiareport.com/2019/03/15/briacell-therapeutics-bct-trading-up-13-6.html.
BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, engages in developing personalized treatments for cancer. Its lead product candidate, Bria-IMT, is being tested in a clinical trial in combination with pembrolizumab (KEYTRUDA; manufactured by Merck & Co, Inc) in patients with advanced breast cancer.
Featured Article: How to Trade Using Analysts Ratings
Receive News & Ratings for Briacell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Briacell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.